PHYS 507 |
| Eliminating suffering and death from cancer requires an unprecedented collaborative effort that leverages resources from government, industry, and academia. Working in concert with the National Institute of Standards and Technology (NIST) and the U.S. Food and Drug Administration (FDA), the National Cancer Institute (NCI) established the Nanotechnology Characterization Laboratory (NCL) to provide critical infrastructure support needed for the rapid development of therapeutics and diagnostics in the field of nanotechnology. Nanomaterials submitted to the NCL are subjected to a standardized analytical cascade that characterizes nanoparticles' physical attributes, their in vitro biological properties, and their in vivo compatibility. Physical attributes such as size, size distribution and surface chemistry are key factors that contribute to a nanomaterial's fate in vivo. The first phase of the assay cascade will therefore focus on characterizing the material's physical properties, including the particle's size, size distribution, purity, surface charge density, molecular weight, composition, surface chemistry, relaxivity and stability. The batch-to-batch reproducibility of material as provided by the sponsor/vendor will also be addressed during this stage. Physico-chemical characterization of several different nanoparticles will be presented employing various analytical techniques relevant to nanotechnology to help determine their physical properties. Nanoparticles presented include dendrimers, nanoemulsions, liposomes, quantum dots, colloidal gold conjugates, MRI contrast agents, fullerenes, and gold nanoshells. Acknowledgement: Funded by NCI Contract N01-CO-12400 |
|
PHYS Poster Session - Nanostructured Materials and Nanophotonics
7:30 PM-10:00 PM, Wednesday, April 9, 2008 Morial Convention Center -- Hall A, Poster
Division of Physical Chemistry |